University of British Columbia (UBC) researchers have led an international team in developing a new test to better diagnose different types of ovarian cancer, a tool that could one day guide and improve treatment options for women diagnosed with the most common and deadliest form of the disease. The development and validation of the test […]
New machine learning method improves testing of stem-like tumor cells for breast cancer research
Prof. Euisik Yoon’s research group has developed a new, faster method to identify cancer stem-like cells (CSCs), which could help improve the effectiveness of cancer treatments. CSCs can seed and develop tumors in metastatic sites, causing cancer to relapse in patients after treatment. They are also generally resistant to chemotherapy and radiotherapy, so therapeutics that […]
Association between outdoor light at night and breast cancer risk among postmenopausal women
Outdoor light at night was linked to a higher risk of breast cancer in a study published in the International Journal of Cancer. For the study, investigators analyzed residential outdoor light at night estimated from satellite imagery in 1996 and assessed rates of breast cancer over 16 years of follow-up in 186,981 postmenopausal women. Compared […]
Genome study links DNA changes to the risks of specific breast cancer subtypes
An analysis of genetic studies covering 266,000 women has revealed 32 new sites on the human genome where variations in DNA appear to alter the risks of getting breast cancer. The study lead and senior authors included researchers at Johns Hopkins Bloomberg School of Public Health. The findings are thought to be the first to […]
World-first saliva test detects hidden throat cancer
A simple saliva test developed by QUT biomedical scientists has detected early throat cancer in a person who had no symptom and no clinical signs of cancer. In what is believed to be a world-first, the non-invasive test picked up HPV-DNA in a saliva sample from an infected healthy person. Persistent human papillomavirus (HPV) infection […]
A new compound removes senescent cells and reduces toxicity in cancer treatment
Senescence is a response to cell damage and stress characterized by the arrest of the cell cycle. When aging, cells permanently stop dividing, thus preventing the propagation of damaged and dysfunctional cells. However, eventually, a massive quantity of senescent cells accumulate in tissues, resulting in the onset and progression of multiple disorders, including diabetes, cardiovascular […]
Therapies show knockout potential for rare, deadly liver cancer
A new study identifies some of the most critical genes that may drive a rare but deadly liver cancer, providing a road map for developing drugs that target those genes. The cancer, fibrolamellar carcinoma, accounts for 1-5% of all liver cancers, and disproportionately affects children and young adults. By the time it is detected it […]
Study reveals an inherited origin of prostate cancer in families
Vanderbilt researchers have identified haplotypes, ancestral fragments of DNA, that are associated with hereditary prostate cancer (HPC) in a first-of-its-kind genomic study made possible by the study of prostate cancer patients with family histories of the disease. The researchers analyzed the Nashville Familial Prostate Cancer Study (NFPCS), in an investigation comparing men with prostate cancer, […]
Certain factors linked with discontinuing breast cancer therapy
For women with hormone receptor-positive breast cancer, long-term endocrine therapy can greatly reduce the risk of recurrence. Many women, especially those in underserved populations, do not continue treatment, however. A new Psycho-Oncology study uncovers some of the factors that may be involved. In the study of 1,231 women who completed questionnaires, 59% reported at least […]
Novel drug targets tumor growth in advanced kidney cancer
Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma in patients with metastatic disease. Researchers from Dana-Farber Cancer Institute report a response rate of 24 percent across all risk categories of patients given an oral first-in-class agent that targets hypoxia inducible factor (HIF) 2-a, […]